Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA <i>EGFR+</i> NSCLC (Except with <i>RB</i> Alterations?) When Adopting Adjuvant Osimertinib.

Although data for OS are immature at the time of this interim analysis, there is no evidence of a detriment on OS, and a positive trend toward improvement in OS [(HR = 0.40; 95% CI: 0.18–0.89) abstracted from the manuscript text] was observed in patients treated with osimertinib.” 31 The US FDA also was neutral in the use of adjuvant chemotherapy based on the data from ADAURA. “Early-stage NSCLC is a life-threatening condition with

also in 11,005 other papers